EASME

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Vital Beats is a developer of a medical platform focused on providing clinical decision support for the remote care of heart patients with pacemakers. The platform employs machine learning and participatory design principles, combined with advanced analytics, to continuously monitor cardiac devices. By utilizing a patent-pending technique, it triages patients effectively, allowing for timely interventions. This approach enhances the management of chronic conditions, ensuring that patients benefit from digital healthcare solutions that monitor their implanted devices around the clock. Vital Beats emphasizes user experience by integrating Nordic aesthetics into its platform, making it both enjoyable and valuable for users.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

ZygoFix is a medical device company focused on spine technology. It has developed a three-dimensional printed implant designed to lock the facet joint of the lumbar spine. This innovative device leverages the anatomy of the spine to provide stability, moving away from traditional external screw-based systems. By eliminating the need for pedicle screws, ZygoFix aims to reduce the risks associated with improper screw placement, enhancing patient safety and outcomes in spinal surgeries.

Limbic is a London-based company that specializes in mental healthcare technology. Founded in 2017, it develops a software development kit (SDK) that leverages machine learning to analyze heart rate data collected from wearable devices like the Apple Watch, allowing for the assessment of users' emotional states. Limbic also offers psychological therapies for adults, focusing on improving mental health through innovative solutions. Its platform supports healthcare professionals by providing tools for stress detection and facilitating clinical assessments, thereby enhancing the efficacy of psychological therapy. By combining AI technology with wearable devices, Limbic aims to address the growing challenges in mental health care and improve patient outcomes.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Espansione Group provides ophthalmology and dermatology products. They provide diagnostic and surgical products in specialized medical fields like ophthalmology, neurology, and ent.

Natac is a company dedicated to investigating, developing, and sustainably manufacturing plant extracts and ingredients of natural origin. Our mission is to grant the nutraceutical, pharmaceutical, food, animal nutrition, and cosmetic industries access to premium, value-added bioactive compounds. Our products are upheld to a level of quality that exceeds the most rigorous standards in the industry. Plant sources are certified additionally through HABOID, a proprietary analytical method, which guarantees the purest botanical products possible. Sustainability is integral to our business model. Natac systematically analyses agricultural processes throughout the botanical industry to discover points in production that have the potential for intervention and investment. Our goal is to use the whole plant in order to access its full potential and thereby reduce the environmental impact of production. Internationally present with established markets around the world, Natac maintains the strategic location of our manufacturing, R&D and Innovation Unit, and Quality Department in Spain, which secures European standards.

Cardiawave, established in late 2014 through a collaboration between the Langevin Institute and the Georges Pompidou European Hospital, specializes in developing non-invasive ultrasonic medical devices aimed at treating heart valve diseases. The company's innovative technology focuses on real-time image guidance to address conditions such as calcified aortic stenosis, minimizing thermal injury and allowing for efficient treatment by clinicians. With a commitment to advancing medical care, Cardiawave has raised over €14 million since its inception to support product development and preclinical studies, paving the way for expected clinical trials to begin. The experienced management team, recognized for its excellence, continues to drive the company's mission to improve patient outcomes in cardiovascular health.

Nateo Healthcare, founded in 2016 and based in Toulouse, France, specializes in designing, developing, and manufacturing medical devices for the fields of gynecology and obstetrics. The company focuses on creating innovative connected medical devices and software that enable healthcare professionals to monitor the health of expectant mothers and their unborn babies. Among its key products is a belt equipped with ultrasound probes that can assess fetal positions, measure the mother's heart rate, and monitor uterine contractions. Additionally, Nateo Healthcare is working on a new generation of mobile and connected fetal heart rate monitors, which facilitate both hospital and home fetal telemonitoring, allowing for enhanced patient self-monitoring and tailored healthcare interventions.

CMI NOV is a healthcare company provides solution for mitral valve repair during open heart surgery.

BioCom is a highly innovative Company in the biomedical sector, focused on research, development and manufacture of cutting-edge medical devices, as well as the development of new technologies for surgery, diagnostics and biomedical research.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Gedea Biotech AB, founded in 2015 and based in Lund, Sweden, focuses on developing an antibiotic-free treatment for vaginal fungal infections, a common issue affecting approximately 75% of women at some point in their lives. The company's key product, GA101, utilizes natural substances to lower vaginal pH, provide physical barrier protection, and inhibit biofilm formation. This innovative approach aims to offer a safe and effective solution for treating and preventing vaginal infections without the use of antibiotics. Gedea Biotech is committed to addressing women's health needs through its unique treatment options.

Brainmarc Ltd. is a company based in Yokne'am, Israel, with an additional location in Hoboken, New Jersey, that specializes in developing a digital platform for cognitive remediation. Founded in 2013, the company utilizes its proprietary Brain Engagement Index (BEI) technology to measure brain engagement and mental activity through electroencephalography (EEG) sensors integrated into headsets. Brainmarc's platform offers therapeutic products aimed at addressing cognitive and mental disorders, demonstrating significant effectiveness in treating cognitive impairments. This technology has been validated through numerous patient cases in clinical settings across the United States, Canada, the European Union, and Israel, providing a reliable solution for measuring attention levels during cognitive exercises.

Nasal is a technology-focused company that specializes in developing automated medical devices for the healthcare sector. It aims to enhance professional practices by providing tools that offer detailed insights into the structure and behavior of the nasal cavity. Through its innovative solutions, Nasal seeks to advance medical simulation technology, thereby assisting and training healthcare professionals. The company's efforts are geared towards improving the quality of care for patients and supporting the ongoing development of medical expertise.

Stokhos started as a scientific mathematical project named REPRO with the aim to reduce ambulance response times. The potential social impact motivated the foundation of Stokhos. We at Stokhos are all very enthusiastic about mathematics and science and are tirelessly working on making the world a safer place. As their products were first developed for he medical emergency market, we have a strong affinity with the medical emergency field. All members of their team, do, for example, have valid first aid certification.

ThermoSiv Technologies specializes in developing advanced heating solutions, focusing on energy efficiency, safety, and health. The company has created ThermoFabric products that utilize carbon-based conductive materials to provide safe and effective far-infrared therapy. These fabrics emit therapeutic rays within the 8-14 micron spectrum, allowing users to warm themselves efficiently while reducing energy consumption during colder months. ThermoSiv addresses critical needs in heating technology that have often been overlooked, offering innovative solutions that promote both comfort and well-being.

Vulcur Medtech is a medical device development company based in Vanløse, Denmark, established in 2018. The company specializes in wound healing through its innovative VMT laser technology, which targets chronic wounds that are otherwise difficult to treat. This advanced device utilizes laser pulses that effectively eliminate biofilm-producing bacteria while preserving healthy human cells, promoting the body's natural healing process. By significantly reducing healing time, Vulcur Medtech enhances the quality of life for patients suffering from chronic wounds.

Yakna develops neurorehabilitation applications and hardware professional education popularization of science.

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Hedia is a health application designed to assist individuals with type 1 and type 2 diabetes by leveraging artificial intelligence. The application analyzes the user's patterns and habits, providing personalized insulin recommendations based on their carbohydrate intake and exercise levels. By facilitating better insulin management, Hedia aims to enhance the everyday lives of people living with diabetes, making it easier for them to control and monitor their condition effectively.

Allergy Data Laboratories continues to manage and support the Allergome project.

Finboot is a company that specializes in blockchain technology, offering an enterprise-grade software-as-a-service product called MARCO. This platform enables organizations to seamlessly integrate blockchain solutions into their value and supply chains across various industries, including Oil & Gas, Chemicals, Consumer Goods, Automotive, Travel, and Healthcare. Established in 2016 with operations in London and Barcelona, Finboot has positioned itself as a leader in the enterprise blockchain sector. MARCO allows businesses to experiment with and validate blockchain applications efficiently, enhancing operational efficiency, reducing costs, and minimizing complexities. The platform emphasizes traceability, transparency, and compliance, thereby supporting organizations in meeting sustainability and environmental, social, and governance (ESG) criteria. Successful implementations of MARCO have improved processes in areas such as quality control in Oil & Gas, environmental sustainability in garment production, and invoice reconciliation in airport logistics, showcasing its potential to transform business operations.

CardiacSense is an innovative start-up on track to revolutionize the Wearable Health Industry by providing affordable, comfortable FDA & CE certified Medical Watches and Wristbands capable of continuous, long term, ambulatory and non-invasive monitoring of life critical functions including Heart Rate, Pulse Rate, Respiratory Rate, Core Temperature, Oxygen Saturation and Blood Pressure. These capabilities enable accurate real time diagnostics of medical conditions such as Heart Arrhythmias (incl. Atrial Fibrillation), Hypertension, COPD, Heart Failure, Sleep Apnea and infections (such as COVID-19).

BIOITHAS research is directed at obtaining unique biotechnological results, generating projects with real value, helping the company to achieve its ultimate aim of working towards scientific results that will improve people’s lives and health.

Arteries Studio Kft. is a Budapest-based firm established in 2003 that specializes in the development of web and mobile applications for businesses in Hungary. The company's web development services encompass the creation of websites, webshops, online software, and Odoo ERP systems. In mobile application development, Arteries Studio focuses on platforms such as iOS, Android, and wearable devices, including smartwatches and Google Glass. Additionally, the company offers graphic design services, which include corporate identity, desktop publishing design, and 3D modeling. Arteries Studio also provides storage and hosting solutions, along with online invoice payment services. Over the years, the studio has collaborated with notable clients, including Unilever, KPMG, NATO, and Bosch, and has increasingly concentrated on creating business applications and health-related web solutions, often integrating external hardware and smart sensors in partnership with manufacturers.

Brain Stimulation AB is a Swedish SME started in 2011 with the aim to provide an efficient assessment and rehabilitation after stroke and traumatic brain injuries. Exploiting brain plasticity results from research within a new concept of rehabilitation and diagnosis of cognitive impairments and disability of attention in stroke patients (Spatial Neglect). They address the global challenge of rehabilitating need for cognitive and upper limb impairments from Stroke, Dementia, Traumatic Brain Injuries, Parkinson and other degenerative brain diseases by using Enriched Rehabilitation.

ABLE Human Motion is a Barcelona-based medical device start-up founded in 2018 that specializes in the development of robotic exoskeletons designed to improve mobility for individuals with disabilities. The company's primary product, the ABLE Exoskeleton, is a lightweight and user-friendly wearable device that assists paraplegic users in standing, walking, and sitting. This innovative technology employs a motor and gearbox to mimic muscle movement, along with an inertial sensor to interpret the user's intentions. ABLE Human Motion aims to enhance the quality of life for wheelchair users by promoting greater independence and mobility while also providing rehabilitation tools for clinicians to improve treatment efficiency.

Healthplus.ai specializes in a surgical patient risk management platform that leverages electronic health record data to enhance surgical care. By utilizing AI and machine learning algorithms, the platform integrates seamlessly with existing EHR workflows to predict potential complications following surgery. This proactive approach allows healthcare professionals to identify early warnings of post-surgery infections and other significant risks, thereby improving patient outcomes and reducing overall costs. Healthplus.ai's technology empowers clinical staff to deliver tailored support to patients, ultimately fostering a more effective and efficient surgical care environment.

Mimetis Biomaterials SL is a Barcelona-based company that specializes in designing and manufacturing biomimetic bone graft substitutes for various medical applications, including dental, craniomaxillofacial, and orthopedic sectors. Founded in 2013, Mimetis focuses on creating synthetic solutions that closely mimic the properties of natural bone to address specific patient needs. The company offers a range of products, including biomimetic granules for filling bone defects, as well as services such as original equipment manufacturing, consulting, and co-development. With over 15 years of research backing its innovations, Mimetis has secured more than 2.5 million euros in public grants and funding to support its growth. The company is currently seeking additional funding to expand its commercial presence in orthopedics and to launch its advanced 3D-printed biomimetic solutions, aimed at improving patient outcomes in complex cases.

EpiGuard is a Norwegian company founded in 2015 by a group of doctors from Oslo University Hospital, alongside co-founders Inven2, Eker Group, and Hansen Protection. The company specializes in the development and manufacture of medical transportation systems designed to safely transfer patients with contagious diseases. EpiGuard's flagship product is a single-patient isolation and transport system that helps prevent the spread of infections to the environment and protects patients from contaminated surroundings. This innovation not only safeguards medical staff but also ensures that patients receive proper care during transport. With expertise spanning various medical fields, including intensive care and infectious diseases, EpiGuard aims to enhance safety and efficiency in patient transport.

BrainPatch is a neurotechnology startup focused on non-invasive brain stimulation. The company develops a computer-brain interface that assists healthcare professionals in measuring brain activity. Its platform integrates artificial intelligence, hardware, and applications, allowing developers, professionals, and patients to conduct brain simulations. This technology aims to facilitate early detection of conditions requiring non-invasive brain stimulation, ultimately aiding patients in their recovery from neurological diseases. BrainPatch recognizes that effective brain stimulation is complex and must be tailored to the individual needs of each patient.

PlatoScience ApS, founded in 2015 and located in Copenhagen, Denmark, specializes in neurostimulation technology through its product, the PlatoWork headset. This device employs transcranial direct current stimulation (tDCS), a non-invasive method that modulates neuronal activity by applying low-intensity currents to the scalp via electrodes. The technology aims to enhance synaptic plasticity and facilitate a targeted mindset, enabling users to achieve deep focus for various tasks. By making neurostimulation accessible and user-friendly, PlatoScience seeks to support mental health and improve cognitive performance, catering to individuals seeking to optimize their mental capabilities.

Lucine has the ambition to transform and improve patient’s health. Their main therapeutic area is pain. The product, a digital therapeutic is able to relieve patient’s pain in 5 minutes through active substances allowing an analgesic neurostimulation. Customized, their solution is adapted to each patient thanks to an instantaneous measurement and analysis of the pain by facial, vocal and postural recognition.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

CSF-Dynamics is developing a new type of hydrocephalus shunt that overcomes the major issues of current shunts on the market. The shunt is currently undergoing clinical testing. CSF-Dynamics expects the shunt to be approved for clinical use by end of year 2021.

Biel Glasses, SL, founded in 2017 and based in Barcelona, Spain, specializes in the development and sale of electronic smart glasses aimed at enhancing mobility and personal autonomy for individuals with low vision. The company’s innovative glasses utilize 3D vision and artificial intelligence algorithms to detect obstacles and environmental changes, translating this information into a format that users can perceive with their remaining vision. Additionally, the glasses feature zoom and image enhancement capabilities, providing a comprehensive solution to support users in navigating their daily lives safely and independently.

Raylytic develops the only fully integrated platform for automated medical image analysis and clinical data extraction. They develop UNITY, the only fully integrated software platform that streamlines the setup and conduct of clinical data collection tasks, including CRFs, PROMs and AI-based medical image analysis. UNITY is utilized to operate private registries, to conduct clinical trials for regulatory approval, post-market surveillance and general medical data collection tasks, providing the basis for evidence based medicine and the backing of product claims with documented, traceable scientific substantiation. Their modular framework utilizes algorithms from industrial and medical image processing as well as sophisticated machine learning algorithms, allowing for the first time the highly automated data extraction and quantification of endpoints based on medical images. The most recent addition is their Clinical Data Module, which seamlessly integrates the electronic capture of patient reported outcome measures (PROMs) into the clinical routine.

Kheiron Medical Technologies Limited is a company focused on enhancing breast cancer detection through its innovative product, Mia, an intelligent assessment tool for mammography. Incorporated in 2016 and based in London with additional offices in San Francisco, Budapest, and Amsterdam, Kheiron aims to improve the efficiency, consistency, and accuracy of radiology reporting by integrating advanced deep learning techniques with radiological expertise. The company's mission is to radically enhance outcomes for cancer patients by advancing precision radiology, thereby providing women with better chances in the fight against cancer. Through ongoing research and development, Kheiron strives to transform cancer detection and treatment, marking a significant step forward in the realm of healthcare technology.

Cyclomics is a Dutch startup focused on revolutionizing cancer care through its proprietary circulating tumor DNA (ctDNA) detection technology. This innovative approach aims to provide faster and more reliable diagnoses, particularly for monitoring cancer recurrence and treatment responses, addressing critical clinical needs that current imaging methods struggle to meet. Cyclomics has developed a diagnostic kit, CyclomicsSeq, which offers superior performance compared to traditional radiological and physical examinations. The initial application of this technology targets head and neck cancers, where effective monitoring of treatment response and recurrence is vital for improving patient survival rates. By enabling accurate measurements and timely interventions, Cyclomics seeks to significantly enhance cancer diagnostics and patient outcomes.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Saphenus has decoded phantom pain and enlarge gait stability through the sense of touch idea and the findings of the medicine nobel price 2021. Globally, millions of amputees face the devastating challenge of phantom pain, with no effective solution available until now. This constant, debilitating pain significantly impacts their quality of life. Saphenus has developed a groundbreaking technology that not only decodes phantom pain but also enhances mobility and stability through an innovative sensory feedback system, redefining what prosthetics can achieve. The urgency of our approach is underscored by the ongoing crisis in conflict zones like Ukraine-Russia and Israel-Palestina. These individuals urgently need faster, pain-free, and effective prosthetic solutions. With the establishment of our partnership with Ternopil Medical University in 2024, Saphenus is uniquely positioned to bring its innovation to those who need it most, offering renewed hope and quality of life. https://www.ukrinform.ua/rubric-regions/3916291-u-ternopoli-vijskovi-otrimali-innovacijni-priladi-do-proteziv-vid-avstrijskoi-kompanii.html Our technology is not just a medical breakthrough but a humanitarian imperative, poised to transform the lives of millions worldwide. Saphenus was awarded 2024 from the European Institute of Technology as one of the 6 best medtech startups in Europe.

TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies. The Company’s principal technology is the CTPIC technology platform that utilizes a non-viral vector to target and destroy cancer cells that over-express certain receptors while simultaneously eliciting an immune response against the cancer cells.

Double Bond Pharmaceutical is a pharmaceutical company focused on developing and commercializing innovative treatments for cancers, infections, autoimmune diseases, and other life-threatening conditions. The company aims to address unmet medical needs by providing more efficient and safer therapeutic options for patients. Through its first-in-class approaches, Double Bond Pharmaceutical seeks to improve patient outcomes and contribute significantly to the healthcare market.

Radiobotics focuses on developing advanced machine learning algorithms that assist healthcare professionals in the analysis of medical images, particularly x-rays of bones and joints. By automating the reading of these images, the company's technology streamlines routine tasks and enhances access to radiology reports. This innovation aims to improve diagnostic quality, supporting doctors in making informed medical decisions more efficiently.

TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

PYRATES Established in 2014 and run by Y-generation women, PYRATES smart fabrics provides the solution to protecting their bodies from the polluted, aggressive external elements that surround us through its PYRATEX®: a textile, health-benefitting armour that protects and cares for the wearer’s body.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

Minnemera is a company based in Stockholm, Sweden, that specializes in developing digital cognitive screening tools. Founded in 2017, the company focuses on creating neurocognitive tests that automatically compare individual results with normative data and personal baseline values to identify abnormalities. This innovative approach aims to enhance the assessment of cognitive function and support healthcare professionals in diagnosing and monitoring cognitive health.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Biom'Up, expert in the field of resorbable biomaterials, designs, develops and manufactures unique medical devices based on collagen technology. These innovative and clinically proven products cover many different surgical specialties - orthopaedics, spinal, cardiac, general and maxillo-facial - and improve patient healing by allowing guided regeneration of soft tissues and bone.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

300K is a start-up founded by and made up of a multidisciplinary team with recognized expertise and proven skills developing and commercializing life sciences innovative products and servicies.

Inflection Biosciences is an early stage, drug development company with a focus on developing innovative small molecule therapeutics that address major unmet needs in cancer. With bases in Dublin and London, the company is dedicated to identifying excellent early stage cancer research from academic institutes and companies around the world. Inflection Biosciences will use its expertise to progress the most promising programs through pre-clinical and early clinical stages, partnering with larger. pharma for later stage clinical development and commercialisation. The company’s founders, including CEO Darren Cunningham and Director of R&D Dr. Michael O’Neill, bring over 60 years of industry experience along with access to a global network of potential partners and service providers.

Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

BalanSeat is a medical device developed by MoPair Technologies Ltd., a company founded by a Feldenkrais practitioner with extensive experience in treating neurologically impaired patients, including those with Multiple Sclerosis, Post-Stroke effects, and Parkinson’s disease. The device is designed specifically for the elderly and individuals with neurological impairments, aiming to enhance walking quality, improve balance, and reduce the risk of falls. BalanSeat achieves this by applying rotational movement between the pelvis, trunk, and thighs, which emulates normal walking patterns while the user remains seated. This innovative approach helps older adults regain essential balance and upper-body rotational movement, contributing to their overall mobility and safety.

SagaNatura is a dynamic Icelandic biotech company, located in one of the most pristine environments on earth – Iceland. SagaNatura focuses on development, production and export of health product from premium Icelandic ingredients. SagaNatura is a leading Icelandic dynamic biotech company, located in one of the most pristine environments on earth – Iceland. SagaNatura‘s focuses on and produces the Icelandic pure, natural form the wild growing organic herb Archangelica Angelica and high-quality Astaxanthin. SagaNatura offers consumer products Icelandic origin that is high quality, safe and vegan-friendly. SagaNatura has two major brands, SagaMedica (est. 2000) and KeyNatura (est. 2014).

ODI Medical specializes in developing innovative technology for the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's medical device streamlines the collection of microvascular data and has diverse clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, and early detection of evolving sepsis. Additionally, the technology is useful for monitoring chronic wounds and conducting mass screenings for conditions such as Ebola, bird flu, and epidemic meningitis. By employing non-invasive techniques, ODI Medical enables healthcare professionals to enhance patient therapy through improved assessment of microcirculation.

ChemoTech is a Scandinavian company based at Medicon Village in Lund, Sweden. The company’s founders have extensive experience of cancer treatment through surgical oncology and clinical development. The company is dedicated to using its unique patented know-how to develop innovation in cancer care through genuine research and clinical trials.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

hystrix medical is a online contracting marketplace for medical devices and replenishing / repeat purchase products in hospitals. Bringing drastic acceleration to the existing 4-6 month procurement process through the establishment of a market price landscape and one-stop- contracting shop for hospital procurers and suppliers alike. Focused on products where the buying and selling require little or no explanation. Targeting efficiency of personnel within hospitals and suppliers - proven average total cost savings of 40% across users.

Stemcis is a medical device manufacturer based in Saint-Denis, France, focused on the research and development of adipose tissue. The company specializes in creating surgical kits designed for the collection, treatment, and re-injection of fat cell preparations. Their work in tissue engineering encompasses both human and veterinary medicine, addressing various pathologies through innovative protocols and medical solutions. Through its commitment to advancing adipose tissue applications, Stemcis aims to enhance treatment options in the medical field.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.

Somax Systems specializes in the development and commercialization of high-performance ultrasound imaging devices tailored for the healthcare sector. The company is on the verge of launching a pocket-sized scanner that is expected to become an essential tool for health professionals, akin to the stethoscope or thermometer. This innovative device offers high-resolution imaging with real-time zoom capabilities and allows for wireless data transmission via Wi-Fi, enhancing the efficiency of healthcare providers. Somax Systems is committed to delivering superior quality products that meet the needs of users and provide sustainable value, grounded in principles of trust, innovation, creativity, and entrepreneurship.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

PlumeSTARS is an innovative PMI specialized in drug delivery to lung for the treatment of respiratory diseases.

Bioengineering Laboratories (BEL) has been conceived as a young, streamlined and multi-faceted organization able to provide technical knowledge and a twenty year experience in designing, testing and producing innovative medical devices in the bioengineering industry. BEL is a pool of professional professionals able to critically address and re-elaborate the key aspects of a “modern” design in the medical field. The knowledge of the market, the openness to new clinical and surgical techniques, the curiosity towards new technologies, the application of an effective Quality System and the constant updating of the current legislative and regulatory requirements are their basis for engineering dedicated to life.

Gondola Medical Technologies is a Swiss company specialized in research and the development of new technologies in the fields of physiotherapy, neurological and osteoarticular rehabilitation. It has developed and brought to the market the GONDOLA™ medical device to give the AMPS treatment, a non-invasive add on therapy to treat motor symptoms in Parkinson's Disease; symptoms that best respond to the GONDOLA™ treatment are Freezing of Gait, walking, slowness of movement and balance. The GONDOLA™ device has been designed to be used at home; its use requires few minutes, and benefits remain for a period ranging from 3 to 5 days. Regular use of the device twice a week allows to maintain benefits overtime.

Biocompatibility Innovation (BCI) is an innovative SME founded in 2014 in Padua (IT) and operating in the field of biotechnologies for biomedical applications. BCI ideates and develops industrial processing and new biomaterials for the manufacture of highly biocompatible implantable prostheses, both biologic and polymeric. The Company is led by a group of experienced researchers and managers in the Biotech and Biomed sectors. Especially, the Founders are recognized for their numerous research and publications in regenerative medicine and tissue engineering of the cardiovascular system. BCI founders were among the first, early in the first decade of 2000, to have started studying the mechanisms of immunological response that trigger the degeneration of implanted bioprostheses. Between 2015 and 2021, BCI conceived and developed the FACTA® (Functional Antigen Cross-linking Targeting Alpha-Gal) technology, an industrial process aimed at extending the lifespan of bioprostheses. FACTA holds a registered trademark and is protected by four patents. In early 2023, a new technology, named PROTEGO, has been developed and patented for the treatment of polymeric and metallic materials used for the manufacture of implantable medical devices. BCI, moreover offers third-party testing services and the development of new proprietary treatments.

DermoSafe is a Swiss company based in Cheseaux, founded in November 2012 by Philippe Held. The company specializes in innovative medical devices designed for the early detection and management of melanoma. Its primary product captures high-definition dermoscopic images of moles and pigmented lesions, allowing general practitioners to enter patient data and refer images to dermatology specialists via a secure web application. This platform facilitates the analysis of images, enabling specialists to provide electronic reports that assist in the early identification of melanoma and the management of treatment. DermoSafe's approach enhances collaboration between primary care practitioners, patients, and specialists, ultimately aiming to improve outcomes in melanoma care.

Eucardia is a company focused on developing innovative medical solutions for advanced heart failure therapy. Its flagship product, the Heart Damper, is a minimally invasive implantable cardiac device designed to offer a straightforward and cost-effective treatment option for patients suffering from advanced heart failure. By improving both the duration and quality of life for these patients, the Heart Damper also aims to alleviate the financial burden on healthcare systems associated with heart failure management.

CRU network has been providing clinical research services to the pharmaceutical industry for over a decade and basic/academic research services since 2015. In the recent years next to the research activities many new healthcare services were initiated within the EU and in South-East Asia. CRU sites are located in Hungary, Ukraine, Germany, Vietnam and LAO PDR.

Dicronis strive to enhance the quality-of-life of patients with their innovative technology. The first product in their pipeline, Lymphit, measures patient’s lymphatic function in a safe, home-based and highly scalable manner. The initial indication of Lymphit is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies. By remotely monitoring the lymphatic function, the physician is enabled for the first time to perform an early diagnosis, before the swelling has occurred, and evaluate the best conservative treatment for the patient. This leads to a great improvement of the prognosis and quality of life of the patient and important savings for the healthcare system and society.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced tests for cancer assessment and personalized treatment. The company offers a range of products including ConfirmMDx, a prostate cancer testing solution that addresses false-negative biopsy concerns; SelectMDx, which helps guide repeat biopsies for prostate cancer; and AssureMDx, a noninvasive liquid biopsy test for bladder cancer that assists in decision-making for cystoscopy. Additionally, MDxHealth provides PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Founded in 2003 and headquartered in Irvine, California, MDxHealth operates additional offices in Herstal, Belgium, and Nijmegen, the Netherlands. The company generates revenue through clinical laboratory services and the out-licensing of its patented DNA methylation platform and biomarkers, serving markets in the United States and Europe.

TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.

Gogoa Mobility Robots is to develop affordable and effective wearable solutions to help humans increase capacity for movement. From neck, shoulder and lumbar support in industrial ergonomics, to health-related critical challenges our bio-mechanical experts create wearable robotics that support human movement. Gogoa's award winning "Assist-As-Needed"​ (AAN) control technology adapts to different human movements. AAN transforms the internal intention to move into actual movement. Our exoskeletons are used in physical rehabilitation and in manufacturing to increase movement capacity for workers and prevent injuries. Designed and made in Europe, Gogoa Mobility Robots has received CE Mark for Hank exoskeleton, allowing it to be sold commercially in Europe.

Filterlex Medical Ltd. is a medical device startup focused on the cardiovascular field, specifically developing an advanced embolic protection device aimed at reducing the risk of stroke and other complications during catheter-based structural heart procedures. The company's innovative device utilizes next-generation technology to address the limitations of existing products. It is designed to be securely positioned in the aorta, providing comprehensive embolic protection by deflecting, capturing, and removing embolic particles. This approach enables physicians to enhance patient safety during these complex procedures. Currently, Filterlex is seeking seed funding to further advance its development efforts.

RegStem is an early stage biopharmaceutical company repurposing molecules and creating new treatments in the fields of regenerative medicine and more specifically in the areas of rare muscle and blood diseases with high unmet medical needs.

RoboFit ApS is a Danish company located in Christiansfeld that specializes in the manufacture and marketing of a rehabilitation robot designed to assist individuals with very weak muscles in exercising their shoulder region. This innovative technology enables patients to train effectively by utilizing the full range of motion of the shoulder, making the rehabilitation process both measurable and motivational.

Arrhythmia Algorithm S.L. (https://rithmi.com) is a privately held company with the mission to support people to take care of their heart and prevent health problems as the stroke. Their aim is to revolutionize the way Auricular fibrillation is diagnosed through a comfortable, compliant and innovative method. After successfully piloting the prototype version of RITHMI technology, the team can confirm the capability of its breakthrough product to open new markets in Europe with the potential for rapid growth. Rithmi is a pioneer in arrhythmia detection technologies and the leading company in Computational Predictive Care™.

ATXA Therapeutics Limited is a spin-out company from University College Dublin whose primary focus is to advance clinical trials and to secure marketing authorization of novel therapies for the treatment of Pulmonary Arterial Hypertension (PAH), serving a previously unmet medical need by offering improved treatment options to the prescribing physician and new hope for the PAH patient. Founded by Professor Therese Kinsella, ATXA was incorporated in May 2015 and is the culmination of over 20 years of extensive research and over €15m of grant funding and a proven track record in understanding of the biology and signalling of the human prostanoid receptors in the cardiovascular disease and oncology setting. Supported with funding from a number of technology and commercialization development grants from Enterprise Ireland and Science Foundation Ireland, ATXA has developed a series of novel, highly selective small molecule drugs, and has identified and validated their potential use in a number of target disease indications including thrombosis/cardiovascular, oncology, anti-inflammatory and, in particular, in PAH. The ATXA team has expertise in cardiovascular and cancer biology with technical expertise in platelet biology, cellular and molecular biology, protein biology, pathological and histopathological and immunohistochemical techniques, digital pathology and biostatistics. In addition, ATXA have experience in drug discovery and early development; lead generation; lead optimization; candidate selection; medicinal chemistry; preclinical pharmacokinetics; intellectual property management and commercialization. ATXA Therapeutics Ltd will advance the late-stage development of their novel therapies that display substantial improvements over the existing standard-of-care, addressing critical unmet medical needs for efficacious new therapies to treat PAH.

720 Degrees Oy specializes in developing a cloud-based analytics solution for monitoring indoor environmental quality. Founded in 2012 and based in Helsinki, Finland, with an additional location in New York, the company offers a range of sensors and software that collect and analyze real-time data on air quality, thermal comfort, and noise pollution. Their air quality sensors measure various parameters, including temperature, relative humidity, carbon dioxide, total volatile organic compounds, and particulate matter. The platform aims to enhance workplace health and satisfaction, allowing organizations and building owners to create optimal working environments. By leveraging artificial intelligence and data-driven insights, 720 Degrees enables businesses to improve office conditions, promote occupational health, and enhance overall job satisfaction and performance.

SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room.

Neurosteer has developed a medical-grade wearable device and cloud-based system aimed at the early detection and treatment of neurological disorders. The solution features an adhesive forehead strip linked to a pocket-sized sensor that wirelessly transmits brain activity data to the cloud for processing. Utilizing advanced algorithms, the system decomposes a single EEG channel into over 100 individual components for real-time analysis, which is displayed on a web-based dashboard. Neurosteer's primary focus is on identifying early signs of conditions such as Parkinson's, Alzheimer's, dementia, and epilepsy. This innovative approach allows for more affordable screening, continuous monitoring of patients, and enhanced neurostimulation and drug selection, ultimately improving the treatment outcomes for neurological disorders and optimizing clinical trials.

Smarterials Technology GmbH, founded in 2016 and headquartered in Berlin, Germany, specializes in the design and development of advanced surgical gloves. These gloves feature a dual-barrier system and perforation indicators that actively alert healthcare professionals to potential infection risks. By providing enhanced protection, Smarterials' products aim to replace traditional double-gloving methods, ultimately reducing the risk of injury and infection for medical staff. The innovative design not only helps prevent contamination from potentially infectious materials but also improves operational efficiency in hospitals and care facilities, allowing for better resource management and cost savings.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Abanza Tecnomed provides research and development of instruments and medical devices specialized in biomedical innovation in the field of sports medicine. Abanza Tecnomed is a research and development company of medical instruments and devices, specialized in biomedical innovation in the field of Sports Medicine. With the commitment to develop and offer the latest generation devices to facilitate the work of medical professionals, ABANZA Tecnomed has a multidisciplinary and highly qualified R&D&I team that guarantees the quality of innovations, and a first-class medical advisory board that certifies the precision and safety of the instruments developed.

GyroGear is a multidisciplinary team composed of designers, engineers, and medical professionals focused on developing innovative solutions for individuals with hand tremors caused by Parkinson's disease and essential tremor. Their flagship product, the GyroGlove, is a wearable device that utilizes advanced aerospace-grade gyroscopes to mechanically stabilize hand tremors. By addressing this critical issue, GyroGear aims to enhance the quality of life, independence, and dignity of those affected by these conditions. The company is dedicated to providing an effective and straightforward solution for managing hand tremors, thereby improving daily functioning for its users.

Cellink is a biotechnology company and one of the first bioink companies in the world. The company leverages its bioink and 3D printing technology to print human organs and tissue models, which potentially can be used in e.g. oncology research, drug testing, and cosmetic testing. The company’s vision is to create the future of medicine by making bioprinting technology as accessible, user-friendly, and high performing as possible. Cellink has offices in Gothenburg, Sweden, and Palo Alto, California, and collaborates with different organizations across the globe.

Airofit is a Danish company that offers a specialized training system designed to strengthen the lungs and improve breathing. Originally developed for medical applications to assist patients with respiratory issues such as asthma and bronchitis, Airofit's equipment focuses on training the diaphragm and intercostal muscles. The system gradually increases the workload on the respiratory system, leading to enhanced breathing power and efficiency. While initially aimed at medical patients, Airofit has proven effective for a broader audience, including athletes seeking to boost endurance and respiratory strength, as well as singers and musicians who benefit from improved coordination and sound quality. The company's innovative approach not only enhances respiratory capacity but also helps reduce the reliance on medications for individuals with chronic respiratory conditions.

Pollen Robotics designs and develops humanoid service robots that cater to the healthcare, retail, and education sectors. These robots are equipped with advanced robotic arms that enable precise object manipulation, facilitating various tasks. Pollen Robotics emphasizes customization and connectivity in its products, allowing users to adapt the robots for different applications. The technology also incorporates features to convey emotions, which enhances interaction and engagement. This innovative approach allows scientists, artists, and innovators to explore new possibilities, making the potential of robotics accessible to a broader audience.

Stayble Therapeutics AB is a clinical-stage pharmaceutical company based in Gothenburg, Sweden, focused on developing an innovative injection treatment for chronic low back pain caused by degenerative disc changes. The company's primary product, STA363, is an intradiscally injected formulation designed for patients who do not experience relief from conventional treatments such as analgesics and physiotherapy. This minimally invasive treatment aims to address the underlying causes of discogenic pain by stabilizing the disc and preventing the leakage of inflammatory mediators. STA363 is administered as a single injection, with the potential for long-lasting effects and minimal rehabilitation requirements. The experienced multidisciplinary team behind Stayble Therapeutics includes renowned researchers and seasoned professionals from the pharmaceutical industry, all dedicated to alleviating the suffering of millions impacted by chronic back pain.

Nimble Robotics designs and sells innovative medical devices for rehabilitation.

Invent Medical's mission is helping people. New technology will constantly disrupt and change the medical field. They apply digital technologies to invent, develop and design a new generation of custom-made orthotic & prosthetic products so patients can experience better treatment outcomes.

Ziccum is developing new dry-powder versions of the world’s most effective vaccines and biologic pharmaceuticals. These new, gently air-dried formulations can be transported easily and cost-effectively, with no costly cold storage or refrigeration required.

Rethink Medical is a medical company that aims to develop innovative medical solutions to various health problems. This includes creating new remedies or significantly improving existing ones. The first product is the T-Control Urinary Catheter. It

Corti is an artificial intelligence platform focused on improving medical triaging through advanced voice-based technology. It enhances patient interactions by analyzing interviews and preparing case files prior to consultations. By utilizing proprietary speech recognition and natural language processing, Corti helps healthcare providers understand patient situations more effectively. The platform also suggests relevant questions to ask during consultations, aiming to reduce errors and increase the accuracy of clinical decisions. Trusted by leading healthcare providers, Corti integrates seamlessly into existing workflows, ultimately striving to save more lives by enabling faster and more precise decision-making in medical care.

BJ Adaptaciones is the leading Spanish company in the distribution of assistive technology nationwide. If your company is interested in marketing its products in thier country, BJ Adaptaciones is your best choice. Their relationship with suppliers is based on close collaboration, as they share the same objective: to bring assistive technology solutions to as many people as possible. To this end, they join forces with suppliers regarding translations, adaptations, marketing campaigns, etc. In the partners section you will find a list of companies they work with. They provide their assistive technology manufacturers with a nationwide sales force, a comprehensive website, a Newsletter aimed at professionals and a wide range of tools to serve all types of clients. They offer training in the form of a support program created to provide professionals with information on assistive technology solutions that are designed and distributed by BJ Adaptations.